Revance Therapeutics Inc. (NASDAQ:RVNC) has earned a consensus rating of “Buy” from the seven brokerages that are currently covering the firm. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $38.80.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 17th. Brean Capital reiterated a “hold” rating on shares of Revance Therapeutics in a report on Friday, August 5th.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2016/11/26/analysts-set-revance-therapeutics-inc-rvnc-pt-at-38-80.html.

Revance Therapeutics (NASDAQ:RVNC) opened at 18.00 on Monday. Revance Therapeutics has a 1-year low of $12.35 and a 1-year high of $40.40. The company’s market capitalization is $513.27 million. The stock’s 50 day moving average is $15.74 and its 200-day moving average is $15.48.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.25. Revance Therapeutics had a negative net margin of 28,187.33% and a negative return on equity of 37.31%. During the same quarter last year, the firm earned ($0.81) EPS. On average, analysts expect that Revance Therapeutics will post ($3.21) earnings per share for the current fiscal year.

In other news, CEO L Daniel Browne sold 12,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 26th. The shares were sold at an average price of $14.85, for a total value of $178,200.00. Following the sale, the chief executive officer now directly owns 219,627 shares of the company’s stock, valued at approximately $3,261,460.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 31.15% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Revance Therapeutics by 11.3% in the second quarter. Vanguard Group Inc. now owns 783,706 shares of the biopharmaceutical company’s stock worth $10,659,000 after buying an additional 79,366 shares during the period. Nationwide Fund Advisors increased its stake in Revance Therapeutics by 96.5% in the second quarter. Nationwide Fund Advisors now owns 33,556 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 16,477 shares during the period. JPMorgan Chase & Co. increased its stake in Revance Therapeutics by 9.9% in the second quarter. JPMorgan Chase & Co. now owns 3,327,022 shares of the biopharmaceutical company’s stock worth $45,247,000 after buying an additional 298,448 shares during the period. Suffolk Capital Management LLC increased its stake in Revance Therapeutics by 64.6% in the second quarter. Suffolk Capital Management LLC now owns 158,812 shares of the biopharmaceutical company’s stock worth $2,160,000 after buying an additional 62,341 shares during the period. Finally, Janney Montgomery Scott LLC bought a new stake in Revance Therapeutics during the second quarter worth about $288,000. 99.96% of the stock is currently owned by institutional investors and hedge funds.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

5 Day Chart for NASDAQ:RVNC

Receive News & Stock Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related stocks with our FREE daily email newsletter.